Antiviral Drugs - China

China

In China, the revenue in the Antiviral Drugs market is forecasted to reach US$4.76bn in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 2.36%, leading to a market volume of US$5.35bn by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to US$30,640.00m in 2024.
China's robust pharmaceutical industry and strong government support have positioned it as a key player in the development and production of antiviral drugs.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Antiviral drugs have become increasingly important in the healthcare sector due to the rise of viral infections globally. In China, the Antiviral Drugs market has been experiencing significant growth in recent years.

Customer preferences: The Chinese population has been increasingly concerned about viral infections, leading to a higher demand for Antiviral Drugs. Additionally, with the aging population, there is a greater need for medication to treat chronic diseases, including viral infections.

Trends in the market: The Antiviral Drugs market in China has been expanding due to the government's efforts to increase healthcare spending and improve access to medication. Additionally, the rise of new viruses and outbreaks has led to an increased demand for Antiviral Drugs. The market has also been witnessing an increase in the development of innovative drugs and therapies.

Local special circumstances: China has a large population, which makes it a significant market for pharmaceutical companies. However, the market is highly regulated, and companies must navigate complex regulatory procedures to bring their products to market. Additionally, the market is highly competitive, with both domestic and international companies vying for market share.

Underlying macroeconomic factors: The Chinese government's focus on improving healthcare infrastructure and increasing healthcare spending has been a significant driver of the Antiviral Drugs market's growth. Additionally, the rise of new viruses and outbreaks has led to increased public awareness of the importance of Antiviral Drugs. The aging population and the increasing prevalence of chronic diseases have also contributed to the market's growth.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.